Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Metal Catalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN101090770B discloses a dual-ligand Rh-catalyzed system for asymmetric hydrogenation, delivering superior enantioselectivity and cost efficiency for API manufacturing.
Patent CN1761642A details an efficient asymmetric hydrogenation process for chiral beta-amino acids, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN102076634A details enantioselective hydrogenation of N-H imines. Discover cost-effective routes for high-purity pharmaceutical intermediates without protection steps.
Patent CN114874134A details a protection-free asymmetric synthesis of nicotine using Ir-catalysis, offering high ee values and scalable manufacturing for pharmaceutical intermediates.
Patent CN120965569A reveals double five-membered ring ligands enhancing stereoselectivity. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN1376659A reveals a safe metal borohydride reduction system for high-purity chiral intermediates, offering significant cost and supply chain advantages.
Advanced preparation of Maropitant intermediates via transition metal catalysis. High purity, >99% ee, and scalable routes for pharmaceutical manufacturing.
Patent CN1568304A reveals a catalytic hydrogenation process for cyclopropylalanine derivatives, ensuring high purity and cost-effective supply chain solutions for global pharmaceutical manufacturers.
Advanced catalytic process for NEP inhibitor intermediates offering superior stereoselectivity. Discover cost-effective manufacturing solutions for complex amino acid derivatives.
Patent CN101279954A details a one-step chiral oxazoline synthesis. This report analyzes cost reduction and supply chain reliability for high-purity pharmaceutical intermediates.
Patent CN111690009A discloses novel Co/Fe complexes for high-ee hydrogenation of alpha-silyl styrenes, offering cost-effective pharma intermediate synthesis.
Patent CN116041393B reveals a novel N-N axis chiral bis-indole phosphine ligand offering superior stereoselectivity for asymmetric allylation and cost-effective pharmaceutical intermediate manufacturing.
Reduce supply chain risks with metal-free deracemization process. 90%+ yield, 95% ee, and scalable production for chiral alcohol intermediates.
Solve low-yield challenges in Balasubramide synthesis. 97% ee, 45% yield, no cytotoxicity. CDMO expertise for scalable production.